BRAF mutations in melanoma

BRAF is a serine/threonine kinase in the MAPK pathway, downstream of RAS and upstream of MEK and ERK. The V600E substitution swaps a buried valine for a glutamate, mimicking phosphorylation in the activation loop and locking the kinase in an active monomeric state independent of upstream RAS signaling. The result is constitutive MAPK signaling, melanocyte proliferation, and resistance to senescence cues.

Non-V600 BRAF alterations behave very differently. Class II mutations (e.g., K601E, L597Q, fusions) form constitutively active dimers that are RAS-independent but require dimer-stable conformations for activity. Class III mutations (e.g., G469E, D594N) have impaired or absent kinase activity and depend on upstream RAS signaling to drive transformation. Class III tumors do not respond to BRAF monotherapy and can paradoxically activate the pathway when treated with first-generation BRAF inhibitors.

Cutaneous melanoma has the highest BRAF mutation rate among solid tumors at roughly 50%. Acral melanoma (~15%) and mucosal melanoma (~5–10%) carry BRAF mutations less frequently. Uveal melanoma rarely carries BRAF mutations and is dominated by GNAQ/GNA11. Across BRAF-mutant cutaneous melanoma, V600E accounts for ~80%, with V600K (~5–15%) and other V600 substitutions making up most of the rest.

Critical distinction: dabrafenib monotherapy in non-V600 BRAF can be ineffective or actively harmful. Tier the variant before treating. Concurrent NRAS or KRAS mutations increase the risk of paradoxical MAPK activation with single-agent BRAF inhibition.

• Dabrafenib + trametinib doublet — first FDA-approved BRAF + MEK combination in V600 melanoma (COMBI-d, COMBI-v).
• Encorafenib + binimetinib doublet — alternative doublet (COLUMBUS); some series show longer PFS in V600 subgroups.
• Atezolizumab + cobimetinib + vemurafenib triplet — adds PD-L1 inhibition (IMspire150). Tier I-A for V600 + immune-checkpoint context.
• Sequential vs concurrent ICI + BRAFi/MEKi — DREAMseq compared first-line combination ICI (nivolumab + ipilimumab) to first-line targeted therapy followed by ICI at progression. First-line ICI showed survival benefit. Patient-selection nuance is real and depends on disease burden, LDH, brain metastases, and prior treatments.

Plasma testing has lower sensitivity for melanoma than for some other tumors. Tissue is the preferred specimen when feasible. Concordance between tissue and plasma improves with higher disease burden and metastatic vs locoregional disease.

Resistance to BRAF + MEK doublet emerges in most patients within 12–18 months. Common mechanisms include:

• NRAS mutations — reactivate the MAPK pathway upstream of BRAF.
• BRAF amplification — increases the kinase pool relative to inhibitor concentration.
• MEK1/MEK2 mutations — bypass MEK inhibition.
• PI3K/AKT pathway alterations — open an alternative survival route.
• Histologic transformation or epithelial-to-mesenchymal-like changes in some tumors.

At progression, immune checkpoint inhibition is the standard next step if not already used. Re-biopsy is appropriate when feasible to identify resistance mechanism for trial referral.

• Cutaneous squamous-cell carcinoma with single-agent BRAF inhibition (paradoxical RAF activation in BRAF-wild-type keratinocytes). MEK combination reduces but does not eliminate the risk.
• Pyrexia with dabrafenib + trametinib — common, often manageable with hold-and-resume protocols. Encorafenib + binimetinib has a different toxicity profile (more retinal events, less pyrexia).
• Cardiomyopathy from MEK inhibition — baseline and serial echocardiography recommended.
• Retinopathy (mostly with binimetinib) — baseline ophthalmologic assessment recommended.

Encorafenib is metabolized via CYP3A4 with substantial QT-interval risk. Strong CYP3A4 inducers and inhibitors require dose review or alternatives. Concurrent QT-prolonging drugs warrant ECG monitoring.

Dabrafenib is also a CYP3A4 substrate and a strong CYP3A4 inducer itself, which can reduce concurrent drug exposures (notable for warfarin, hormonal contraceptives, and many oncology agents). Drug-interaction review is essential.

• CIViC — BRAF V600E + dabrafenib + trametinib (Tier I-A).
• ClinVar — BRAF variant pathogenicity classifications.
• PubMed 25265492 — Long et al., COMBI-d, NEJM 2014.
• PubMed 30219628 — Dummer et al., COLUMBUS, Lancet Oncol 2018.
• PubMed 32918873 — Gutzmer et al., IMspire150, Lancet 2020.
• AMP/ASCO/CAP 2017 — Li MM et al., J Mol Diagn 2017;19(1):4-23.
• openFDA labels for dabrafenib, trametinib, encorafenib, binimetinib, vemurafenib, cobimetinib, atezolizumab.

• Decision-support reference, not CAP/CLIA-validated diagnostic.
• BRAF V600E in colorectal cancer is treated with encorafenib + cetuximab (BEACON CRC), not the dabrafenib + trametinib doublet used in melanoma. Tumor type drives drug selection alongside variant status.
• BRAF V600E in NSCLC, anaplastic thyroid cancer, and tissue-agnostic indications all have distinct labels.
• Drug-trial recruiting status changes daily. ClinicalTrials.gov is the source of truth.

What is the first-line targeted therapy for BRAF V600E melanoma?

Doublet BRAF + MEK inhibition is the standard targeted first-line: dabrafenib + trametinib (COMBI-d) or encorafenib + binimetinib (COLUMBUS). Triplet combinations adding immune checkpoint inhibition (IMspire150) are also FDA-approved. Sequencing with immunotherapy depends on disease burden and patient factors.

Why is single-agent BRAF inhibition not used in non-V600 BRAF melanoma?

Class II and Class III BRAF alterations behave differently from V600. Single-agent BRAF inhibition can be ineffective and may cause paradoxical MAPK activation. Tier the variant before selecting therapy.

Are BRAF V600E mutations treated the same way across cancer types?

No. BRAF V600E in colorectal cancer uses encorafenib + cetuximab (BEACON CRC), differing from the dabrafenib + trametinib doublet in melanoma. The drug-gene match depends on tumor type.